^
Association details:
| Biomarker: | KRAS G12C + KRAS G12V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | AZ’8037 (KRAS G12C inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
Published date:
02/17/2022
Excerpt:
Introducing KRAS c.35G>T in trans in the KRAS G12C lung cancer model NCI-H358, as well as the co-occurrence in cis in the KRAS G12F lung cancer model NCI-H2291 led to cellular resistance to the G12C-specific inhibitor AZ'8037...Overall, our study provides a comprehensive assessment of co-occurring KRAS mutations in NSCLC and in vitro evidence of the negative impact of co-occurring KRAS mutations on cellular response to G12C inhibitors.
DOI:
10.1038/s41598-022-06369-3
